[1] |
SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3)[J]. JAMA,2016,315(8):801-810. doi: 10.1001/jama.2016.0287 |
[2] |
RUDD K E, JOHNSON S C, AGESA K M, et al. Global, regional, and national Sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet,2020,395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7 |
[3] |
VENET F, MONNERET G. Advances in the understanding and treatment of Sepsis-induced immunosuppression[J]. Nat Rev Nephrol,2018,14(2):121-137. doi: 10.1038/nrneph.2017.165 |
[4] |
张文钊, 王志斌. 脓毒症免疫抑制相关效应T细胞亚群稳态失衡的研究进展[J]. 中华危重病急救医学, 2022(1):95-99. doi: 10.3760/cma.j.cn121430-20210610-00858 |
[5] |
FISHER C J Jr, AGOSTI J M, OPAL S M, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group[J]. N Engl J Med,1996,334(26):1697-1702. doi: 10.1056/NEJM199606273342603 |
[6] |
ABRAHAM E, GLAUSER M P, BUTLER T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe Sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group[J]. JAMA,1997,277(19):1531-1538. doi: 10.1001/jama.1997.03540430043031 |
[7] |
OPAL S M, LATERRE P F, FRANCOIS B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe Sepsis: the ACCESS randomized trial[J]. JAMA,2013,309(11):1154-1162. doi: 10.1001/jama.2013.2194 |
[8] |
RICE T W, WHEELER A P, BERNARD G R, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe Sepsis[J]. Crit Care Med,2010,38(8):1685-1694. doi: 10.1097/CCM.0b013e3181e7c5c9 |
[9] |
BURGESS A W, METCALF D. The nature and action of granulocyte-macrophage colony stimulating factors[J]. Blood,1980,56(6):947-958. doi: 10.1182/blood.V56.6.947.947 |
[10] |
MATHIAS B, SZPILA B E, MOORE F A, et al. A review of GM-CSF therapy in Sepsis[J]. Medicine,2015,94(50):e2044. doi: 10.1097/MD.0000000000002044 |
[11] |
HAMILTON J A. GM-CSF in inflammation[J]. J Exp Med,2020,217(1):e20190945. doi: 10.1084/jem.20190945 |
[12] |
FRYDRYCH L M, BIAN G W, FATTAHI F, et al. GM-CSF administration improves defects in innate immunity and Sepsis survival in obese diabetic mice[J]. J Immunol,2019,202(3):931-942. doi: 10.4049/jimmunol.1800713 |
[13] |
LI Y M, ZHAI P, ZHENG Y W, et al. Csf2 attenuated Sepsis-induced acute kidney injury by promoting alternative macrophage transition[J]. Front Immunol,2020,11:1415. doi: 10.3389/fimmu.2020.01415 |
[14] |
PRESNEILL J J, HARRIS T, STEWART A G, et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe Sepsis with respiratory dysfunction[J]. Am J Respir Crit Care Med,2002,166(2):138-143. doi: 10.1164/rccm.2009005 |
[15] |
DROSSOU-AGAKIDOU V, KANAKOUDI-TSAKALIDOU F, SARAFIDIS K, et al. In vivo effect of rhGM-CSF And rhG-CSF on monocyte HLA-DR expression of septic neonates[J]. Cytokine,2002,18(5):260-265. doi: 10.1006/cyto.2002.1037 |
[16] |
MEISEL C, SCHEFOLD J C, PSCHOWSKI R, et al. Granulocyte-macrophage colony-stimulating factor to reverse Sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial[J]. Am J Respir Crit Care Med,2009,180(7):640-648. doi: 10.1164/rccm.200903-0363OC |
[17] |
HALL M W, KNATZ N L, VETTERLY C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome[J]. Intensive Care Med,2011,37(3):525-532. doi: 10.1007/s00134-010-2088-x |
[18] |
LEENTJENS J, KOX M, KOCH R M, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study[J]. Am J Respir Crit Care Med,2012,186(9):838-845. doi: 10.1164/rccm.201204-0645OC |
[19] |
TEMESGEN Z, ASSI M, SHWETA F N U, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study[J]. Mayo Clin Proc,2020,95(11):2382-2394. doi: 10.1016/j.mayocp.2020.08.038 |
[20] |
DE LUCA G, CAVALLI G, CAMPOCHIARO C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study[J]. Lancet Rheumatol,2020,2(8):e465-e473. doi: 10.1016/S2665-9913(20)30170-3 |
[21] |
BOEHM U, KLAMP T, GROOT M, et al. Cellular responses to interferon-gamma[J]. Annu Rev Immunol,1997,15:749-795. doi: 10.1146/annurev.immunol.15.1.749 |
[22] |
DÖCKE W D, RANDOW F, SYRBE U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment[J]. Nat Med,1997,3(6):678-681. doi: 10.1038/nm0697-678 |
[23] |
DELSING C E, GRESNIGT M S, LEENTJENS J, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series[J]. BMC Infect Dis,2014,14:166. doi: 10.1186/1471-2334-14-166 |
[24] |
WARD J D, CORNABY C, SCHMITZ J L. Indeterminate QuantiFERON gold plus results reveal deficient interferon gamma responses in severely ill COVID-19 patients[J]. J Clin Microbiol,2021,59(10):e0081121. doi: 10.1128/JCM.00811-21 |
[25] |
DICKEL S, GRIMM C, AMSCHLER K, et al. Case report: interferon-γ restores monocytic human leukocyte antigen receptor (mHLA-DR) in severe COVID-19 with acquired immunosuppression syndrome[J]. Front Immunol,2021,12:645124. doi: 10.3389/fimmu.2021.645124 |
[26] |
KIM E Y, NER-GAON H, VARON J, et al. Post-Sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells[J]. J Clin Invest,2020,130(6):3238-3252. doi: 10.1172/JCI128075 |
[27] |
BARATA J T, DURUM S K, SEDDON B. Flip the coin: IL-7 and IL-7R in health and disease[J]. Nat Immunol,2019,20(12):1584-1593. doi: 10.1038/s41590-019-0479-x |
[28] |
DELWARDE B, PERONNET E, VENET F, et al. Low interleukin-7 receptor messenger RNA expression is independently associated with day 28 mortality in septic shock patients[J]. Crit Care Med,2018,46(11):1739-1746. doi: 10.1097/CCM.0000000000003281 |
[29] |
UNSINGER J, MCGLYNN M, KASTEN K R, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in Sepsis[J]. J Immunol,2010,184(7):3768-3779. doi: 10.4049/jimmunol.0903151 |
[30] |
UNSINGER J, BURNHAM C A D, MCDONOUGH J, et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal Sepsis[J]. J Infect Dis,2012,206(4):606-616. doi: 10.1093/infdis/jis383 |
[31] |
SHINDO Y, FUCHS A G, DAVIS C G, et al. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia[J]. J Leukoc Biol,2017,101(2):543-554. doi: 10.1189/jlb.4A1215-581R |
[32] |
KASTEN K R, PRAKASH P S, UNSINGER J, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of Sepsis[J]. Infect Immun,2010,78(11):4714-4722. doi: 10.1128/IAI.00456-10 |
[33] |
THAMPY L K, REMY K E, WALTON A H, et al. Restoration of T Cell function in multi-drug resistant bacterial Sepsis after interleukin-7, anti-PD-L1, and OX-40 administration[J]. PLoS One,2018,13(6):e0199497. doi: 10.1371/journal.pone.0199497 |
[34] |
VENET F, FORAY A P, VILLARS-MÉCHIN A, et al. IL-7 restores lymphocyte functions in septic patients[J]. J Immunol,2012,189(10):5073-5081. doi: 10.4049/jimmunol.1202062 |
[35] |
VENET F, DEMARET J, BLAISE B J, et al. IL-7 restores T lymphocyte immunometabolic failure in septic shock patients through mTOR activation[J]. J Immunol,2017,199(5):1606-1615. doi: 10.4049/jimmunol.1700127 |
[36] |
FRANCOIS B, JEANNET R, DAIX T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial[J]. JCI Insight,2018,3(5):e98960. doi: 10.1172/jci.insight.98960 |
[37] |
ADAMO S, CHEVRIER S, CERVIA C, et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19[J]. Allergy,2021,76(9):2866-2881. doi: 10.1111/all.14866 |
[38] |
REMY K E, MAZER M, STRIKER D A, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections[J]. JCI Insight,2020,5(17):e140329. doi: 10.1172/jci.insight.140329 |
[39] |
LATERRE P F, FRANÇOIS B, COLLIENNE C, et al. Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19)[J]. JAMA Netw Open,2020,3(7):e2016485. doi: 10.1001/jamanetworkopen.2020.16485 |
[40] |
KANDIKATTU H K, VENKATESHAIAH S U, KUMAR S, et al. IL-15 immunotherapy is a viable strategy for COVID-19[J]. Cytokine Growth Factor Rev,2020,54:24-31. doi: 10.1016/j.cytogfr.2020.06.008 |
[41] |
INOUE S, UNSINGER J, DAVIS C G, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in Sepsis[J]. J Immunol,2010,184(3):1401-1409. doi: 10.4049/jimmunol.0902307 |
[42] |
SAITO M, INOUE S, YAMASHITA K, et al. IL-15 improves aging-induced persistent T cell exhaustion in mouse models of repeated Sepsis[J]. Shock,2020,53(2):228-235. doi: 10.1097/SHK.0000000000001352 |
[43] |
ZHAO X Y, QI H, ZHOU J M, et al. Treatment with recombinant interleukin-15 (IL-15) increases the number of T cells and natural killer (NK) cells and levels of interferon-γ (IFN-γ) in a rat model of Sepsis[J]. Med Sci Monit,2019,25:4450-4456. doi: 10.12659/MSM.914026 |
[44] |
ORINSKA Z, MAURER M, MIRGHOMIZADEH F, et al. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities[J]. Nat Med,2007,13(8):927-934. doi: 10.1038/nm1615 |
[45] |
GUO Y, LUAN L M, PATIL N K, et al. IL-15 enables septic shock by maintaining NK cell integrity and function[J]. J Immunol,2017,198(3):1320-1333. doi: 10.4049/jimmunol.1601486 |
[46] |
BRAHMAMDAM P, INOUE S, UNSINGER J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during Sepsis[J]. J Leukoc Biol,2010,88(2):233-240. doi: 10.1189/jlb.0110037 |
[47] |
CHANG K C, BURNHAM C A, COMPTON S M, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal Sepsis[J]. Crit Care,2013,17(3):R85. doi: 10.1186/cc12711 |
[48] |
CHANG K, SVABEK C, VAZQUEZ-GUILLAMET C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with Sepsis[J]. Crit Care,2014,18(1):R3. doi: 10.1186/cc13176 |
[49] |
ZHANG Y, ZHOU Y, LOU J S, et al. PD-L1 blockade improves survival in experimental Sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction[J]. Crit Care,2010,14(6):R220. doi: 10.1186/cc9354 |
[50] |
WANG J F, WANG Y P, XIE J, et al. Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of Sepsis[J]. Blood,2021,138(9):806-810. doi: 10.1182/blood.2020009417 |
[51] |
TRIANTAFYLLOU E, GUDD C L, MAWHIN M A, et al. PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury[J]. J Clin Invest,2021,131(4):e140196. doi: 10.1172/JCI140196 |
[52] |
BOOMER J S, SHUHERK-SHAFFER J, HOTCHKISS R S, et al. A prospective analysis of lymphocyte phenotype and function over the course of acute Sepsis[J]. Crit Care,2012,16(3):R112. doi: 10.1186/cc11404 |
[53] |
INOUE S, BO L L, BIAN J J, et al. Dose-dependent effect of anti-CTLA-4 on survival in Sepsis[J]. Shock,2011,36(1):38-44. doi: 10.1097/SHK.0b013e3182168cce |
[54] |
MEWES C, ALEXANDER T, BÜTTNER B, et al. TIM-3 genetic variants are associated with altered clinical outcome and susceptibility to gram-positive infections in patients with Sepsis[J]. Int J Mol Sci,2020,21(21):8318. doi: 10.3390/ijms21218318 |
[55] |
HUANG S Y, LIU D, SUN J H, et al. Tim-3 regulates Sepsis-induced immunosuppression by inhibiting the NF-κB signaling pathway in CD4 T cells[J]. Mol Ther,2022,30(3):1227-1238. doi: 10.1016/j.ymthe.2021.12.013 |
[56] |
WEI Z P, LI P F, YAO Y, et al. Alpha-lactose reverses liver injury via blockade of Tim-3-mediated CD8 apoptosis in Sepsis[J]. Clin Immunol,2018,192:78-84. doi: 10.1016/j.clim.2018.04.010 |
[57] |
YAO Y, DENG H, LI P F, et al. Α-lactose improves the survival of septic mice by blockade of TIM-3 signaling to prevent NKT cell apoptosis and attenuate cytokine storm[J]. Shock,2017,47(3):337-345. doi: 10.1097/SHK.0000000000000717 |
[58] |
XIA Q, WEI L, ZHANG Y T, et al. Immune checkpoint receptors tim-3 and PD-1 regulate monocyte and T lymphocyte function in septic patients[J]. Mediators Inflamm,2018,2018:1632902. |
[59] |
LOU J S, WANG J F, FEI M M, et al. Targeting lymphocyte activation gene 3 to reverse T-lymphocyte dysfunction and improve survival in murine polymicrobial Sepsis[J]. J Infect Dis,2020,222(6):1051-1061. doi: 10.1093/infdis/jiaa191 |
[60] |
SHERWOOD E R, HOTCHKISS R S. BTLA as a biomarker and mediator of Sepsis-induced immunosuppression[J]. Crit Care,2013,17(6):1022. doi: 10.1186/cc13143 |
[61] |
SHUBIN N J, MONAGHAN S F, HEFFERNAN D S, et al. B and T lymphocyte attenuator expression on CD4+ T-cells associates with Sepsis and subsequent infections in ICU patients[J]. Crit Care,2013,17(6):R276. doi: 10.1186/cc13131 |
[62] |
WANG W D, YANG X R, GUO M F, et al. Up-regulation of BTLA expression in myeloid dendritic cells associated with the treatment outcome of neonatal Sepsis[J]. Mol Immunol,2021,134:129-140. doi: 10.1016/j.molimm.2021.03.007 |
[63] |
SHUBIN N J, CHUNG C S, HEFFERNAN D S, et al. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction[J]. J Leukoc Biol,2012,92(3):593-603. doi: 10.1189/jlb.1211641 |
[64] |
SHAO R, LI C S, FANG Y Y, et al. Low B and T lymphocyte attenuator expression on CD4+ T cells in the early stage of Sepsis is associated with the severity and mortality of septic patients: a prospective cohort study[J]. Crit Care,2015,19(1):308. doi: 10.1186/s13054-015-1024-4 |
[65] |
KOBAYASHI Y, IWATA A, SUZUKI K, et al. B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells[J]. Proc Natl Acad Sci USA,2013,110(13):5121-5126. doi: 10.1073/pnas.1222093110 |
[66] |
SUN Y N, DING R Y, CHANG Y K, et al. Immune checkpoint molecule TIGIT manipulates T cell dysfunction in septic patients[J]. Int Immunopharmacol, 2021, 101(Pt B): 108205. |
[67] |
MENG Y, ZHAO Z Z, ZHU W Z, et al. CD155 blockade improves survival in experimental Sepsis by reversing dendritic cell dysfunction[J]. Biochem Biophys Res Commun,2017,490(2):283-289. doi: 10.1016/j.bbrc.2017.06.037 |
[68] |
ZHANG W X, ANYALEBECHI J C, RAMONELL K M, et al. TIGIT modulates Sepsis-induced immune dysregulation in mice with preexisting malignancy[J]. JCI Insight,2021,6(11):e139823. doi: 10.1172/jci.insight.139823 |
[69] |
UNSINGER J, WALTON A H, BLOOD T, et al. Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in Sepsis[J]. J Leukoc Biol,2021,109(4):697-708. doi: 10.1002/JLB.5HI0720-043R |
[70] |
WAN J, SHAN Y, SHAN H W, et al. Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice[J]. Front Biosci (Landmark Ed),2011,16(8):3004-3013. |
[71] |
Zhang Y, Xia D, Li L, et al. Thymosin α1 alleviates lung injury in Sepsis rats via Notch signaling pathway[J]. Panminerva Med,2020:2020Feb18. |
[72] |
XIANG X S, LI N, ZHAO Y Z, et al. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive Sepsis[J]. Inflammation,2014,37(2):402-416. doi: 10.1007/s10753-013-9753-5 |
[73] |
ZHANG D Q, ZHOU Y, CHENG Q H. Effects of combined thymosin and hydrocortisone on immune response in septic mice[J]. Int J Clin Exp Med,2015,8(8):12989-12994. |
[74] |
ZHANG Y, CHEN H, LI Y M, et al. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for Sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria[J]. J Infect Dis,2008,198(5):723-730. doi: 10.1086/590500 |
[75] |
HAN D, SHANG W L, WANG G Z, et al. Ulinastatin- and thymosin α1-based immunomodulatory strategy for Sepsis: a meta-analysis[J]. Int Immunopharmacol,2015,29(2):377-382. doi: 10.1016/j.intimp.2015.10.026 |
[76] |
CHEN J. Effects of thymosin-alpha1 on cell immunity function in patients with septic shock[J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue,2007,19(3):153-155. |
[77] |
WU J F, ZHOU L X, LIU J Y, et al. The efficacy of thymosin alpha 1 for severe Sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial[J]. Crit Care,2013,17(1):R8. doi: 10.1186/cc11932 |
[78] |
LIU Y P, PAN Y, HU Z H, et al. Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells[J]. Clin Infect Dis,2020,71(16):2150-2157. doi: 10.1093/cid/ciaa630 |
[79] |
WANG Z Y, CHEN J, ZHU C Y, et al. Thymosin alpha-1 has no beneficial effect on restoring CD4+ and CD8+ T lymphocyte counts in COVID-19 patients[J]. Front Immunol,2021,12:568789. doi: 10.3389/fimmu.2021.568789 |
[80] |
HUANG C L, FEI L, XU W, et al. Efficacy evaluation of thymosin alpha 1 in non-severe patients with COVID-19: a retrospective cohort study based on propensity score matching[J]. Front Med (Lausanne),2021,8:664776. |
[81] |
SUN Q, XIE J F, ZHENG R Q, et al. The effect of thymosin α1 on mortality of critical COVID-19 patients: a multicenter retrospective study[J]. Int Immunopharmacol,2021,90:107143. doi: 10.1016/j.intimp.2020.107143 |
[82] |
LIU J, SHEN Y F, WEN Z L, et al. Efficacy of thymosin alpha 1 in the treatment of COVID-19: a multicenter cohort study[J]. Front Immunol,2021,12:673693. doi: 10.3389/fimmu.2021.673693 |
[83] |
CUI J, WEI X X, LV H J, et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in Sepsis or septic shock: a meta-analysis with trial sequential analysis[J]. Ann Intensive Care,2019,9(1):27. doi: 10.1186/s13613-019-0501-3 |
[84] |
DOMIZI R, ADRARIO E, DAMIANI E, et al. IgM-enriched immunoglobulins (Pentaglobin) may improve the microcirculation in Sepsis: a pilot randomized trial[J]. Ann Intensive Care,2019,9(1):135. doi: 10.1186/s13613-019-0609-5 |
[85] |
WAND S, KLAGES M, KIRBACH C, et al. IgM-enriched immunoglobulin attenuates systemic endotoxin activity in early severe Sepsis: a before-after cohort study[J]. PLoS One,2016,11(8):e0160907. doi: 10.1371/journal.pone.0160907 |
[86] |
OZCAN P E, SENTURK E, ORHUN G, et al. Effects of intravenous immunoglobulin therapy on behavior deficits and functions in Sepsis model[J]. Ann Intensive Care,2015,5(1):62. |
[87] |
GIAMARELLOS-BOURBOULIS E J, TZIOLOS N, ROUTSI C, et al. Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins[J]. Clin Microbiol Infect,2016,22(6):499-506. doi: 10.1016/j.cmi.2016.01.021 |
[88] |
吴健锋, 栾樱译, 柯路. 脓毒症免疫抑制诊治专家共识[J]. 中华危重病急救医学, 2020(11):1281-1289. |